# Evaluation of ivermectin as an antimalarial therapy against P. falciparum liver stage

> **NIH NIH R21** · UNIVERSITY OF SOUTH FLORIDA · 2020 · $204,036

## Abstract

Project Summary/Abstract
Ivermectin mass drug administration (MDA) is proposed as a novel malaria transmission control tool to kill the
mosquito vectors. Where Ivermectin MDA has been examined and found to be effective against the
transmission of Plasmodium berghei, it unclear if this translates to human malaria. The objective of this study is
to determine if Ivermectin MDA, when combined with other antimalarial drug treatments, could be effective in
eliminating P. falciparum transmission, aiding in the malaria eradication initiative. Ivermectin metabolites will be
identified using metabolically-active primary human hepatocytes in the liver stage development assay.
Leveraging these data as the baseline, pharmacokinetic drug-drug interactions will be evaluated between
ivermectin and artemisinin-based combination therapies to be analyzed in future clinical trials. These methods
will also utilize the primary human hepatocyte liver stage assay as a way to obtain metabolites and further
examine them via LC-MS.

## Key facts

- **NIH application ID:** 10001705
- **Project number:** 1R21AI149730-01A1
- **Recipient organization:** UNIVERSITY OF SOUTH FLORIDA
- **Principal Investigator:** John H Adams
- **Activity code:** R21 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2020
- **Award amount:** $204,036
- **Award type:** 1
- **Project period:** 2020-05-22 → 2022-04-30

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10001705

## Citation

> US National Institutes of Health, RePORTER application 10001705, Evaluation of ivermectin as an antimalarial therapy against P. falciparum liver stage (1R21AI149730-01A1). Retrieved via AI Analytics 2026-05-22 from https://api.ai-analytics.org/grant/nih/10001705. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*